Reuters: IPOX® Analyst Muehlbauer Comments on Medline’s Blockbuster U.S. IPO Filing

Reuters reported that Medline, one of the world’s largest makers of medical supplies, has publicly filed for its highly anticipated U.S. IPO, a move that could value the company at up to $50 billion. The filing underscores renewed momentum in the IPO market, which has shown strong signs of recovery following several years of subdued activity.

In the article, IPOX® Research Associate Lukas Muehlbauer provided insight into the offering’s broader significance for the market, stating:

“As what is expected to be this year's largest deal, the offering signals that the IPO market remains wide open despite the shutdown. Medline's performance will be a critical barometer for investor confidence extending into 2026, not just in the healthcare sector.”

Muehlbauer also noted that Medline’s journey, from its first IPO in 1972 to its current position as a global healthcare supply leader, reflects a “classic American growth story.”

The company, backed by Blackstone, Carlyle, and Hellman & Friedman, reported a 9.7% rise in revenue in the first half of 2025. Its IPO, expected to be among the largest of the year, will list on the Nasdaq under the ticker symbol MDLN.

Read the full article by Manya Saini and Arasu Basil on Reuters:
https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-giant-medline-reveals-us-ipo-filing-2025-10-28/

Read our recent IPOX® Watch - Pre-IPO Analysis feature on Medline:
https://www.ipox.com/ipox/ipox-watch-medline